Fosun Pharma forecasts 2026 transactions, renews subsidiary loan

Shanghai Fosun Pharmaceutical Group has announced its forecast for 2026 daily connected transactions, estimating a total value of 36,650 yuan. This includes transactions with various related parties such as Fosun Foundation, United Health Insurance, and Huaihai Hospital, covering sales, purchases, service provisions, property rentals, and donations. These transactions are deemed necessary and ongoing, reflecting the Group's operational model.

Additionally, Fosun Pharma's board has approved the renewal of a loan facility for its controlled subsidiary, Fosun Health Cloud, totaling 6,550 yuan. This loan will be extended for 12 months until December 4, 2026, with an adjusted annual interest rate of 3.2%. The renewal aligns with previously approved internal lending limits and does not require further shareholder approval.

The Group also renewed its framework agreements with Fosun International for 2026, covering product and service interchange, as well as property leasing. These agreements facilitate ongoing operational needs, with estimated annual caps for various transaction categories, including product sales (3,000 yuan), product procurement (2,500 yuan), and service provisions (5,000 yuan).